Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS006 Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumors
NCT05061628Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of JS006 in advanced cancer (2 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Safety and Tolerability at 2 years and Maximum Tolerated Dose and Recommended Phase II Dose at 2 years. Started Apr 2021; status: completed.
02
Drugs
JS006
03
Conditions
advanced cancer
Beyond the preview
Go deeper on NCT05061628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061628.